They were removed from Category 2 in 2024 only because the nominations were withdrawn, not because they were judged safe
Neuroinflammation Neurogenic inflammation describes the phenomenon of arteriolar vasodilation, plasma protein extravasation, and degranulation of mast cells, caused by the release of potent vasoactive neuropeptides (mainly CGRP, substance P, and neurokinin A) from activated peripheral nociceptive nerve terminals
In a 2024 joint court filing, the two companies said that the safety profile of GLP-1 RAs has been well-established in hundreds of clinical trials, large-scale observational studies, and nearly two decades of real-world use
9 The diversity of tumor cells at the genetic, transcriptomic, epigenetic, and phenotypic levels gives rise to intratumoral heterogeneity, which underlies the wide variability in treatment responses
That surge created a new executive question: if injectables can scale to this extent, what happens when convenience barriers falland access expands from specialist-led injection ecosystems to routine oral prescribing